OncoMatch/Clinical Trials/NCT06554600
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Is NCT06554600 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Zanubrutinib and Polatuzumab Vedotin for refractory or relapsed diffuse large b cell lymphoma.
Treatment: Zanubrutinib · Polatuzumab Vedotin · Bendamustine · Rituximab — This is a prospective, multicenter, single-arm, open phase II study to explore the efficacy and safety of Zanubrutinib in combination with Polatuzumab Vedotin, bendamustine, and rituximab (Polo-ZBR) in subjects with relapsed/refractory diffuse large B-cell lymphoma. Subjects with relapsed/refractory DLBCL who met the inclusion/exclusion criteria were screened and treated with 4 courses of Pola-ZBR regimen after signing informed consent. Subjects achieving PR or CR were consolidated with autologous transplantation consolidation or the original regimen for 2 additional courses, and then given Zanubrutinib maintenance therapy for 1 year. The final follow-up was observed until 2 years after enrollment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: BCL6 rearrangement
Allowed: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunochemotherapy — first-line
no response after first-line treatment (including immunochemotherapy, chemotherapy or hematopoietic stem cell transplantation) or relapsed or refractory after remission
Must have received: chemotherapy — first-line
no response after first-line treatment (including immunochemotherapy, chemotherapy or hematopoietic stem cell transplantation) or relapsed or refractory after remission
Must have received: hematopoietic stem cell transplantation — first-line
no response after first-line treatment (including immunochemotherapy, chemotherapy or hematopoietic stem cell transplantation) or relapsed or refractory after remission
Cannot have received: organ transplantation
Have received organ transplantation or allogeneic stem cell transplantation
Cannot have received: allogeneic stem cell transplantation
Have received organ transplantation or allogeneic stem cell transplantation
Cannot have received: other antitumor drugs
Exception: within 2 weeks prior to medication in this study
Patients who could not stop using any other antitumor drugs within 2 weeks prior to medication in this study
Lab requirements
Blood counts
Leukocyte count ≥ 3.5×10^9/L, neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L, hemoglobin ≥ 100g/L
Kidney function
creatinine ≤ 1.5x ULN
Liver function
ALT or AST ≤ 2.5x ULN, bilirubin ≤ 1.5x ULN
Laboratory test value at screening (unless due to lymphoma) : Leukocyte count < 3.5×10^9/L, neutrophils <1.5×10^9/L, platelets <80×10^9/L, hemoglobin <100g/L, ALT or AST were 2.5 times higher than the upper limit of normal, bilirubin was 1.5 times higher than the upper limit of normal, creatinine level was 1.5 times higher than the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify